Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection
Condition(s) studied
Investigational drug(s) / intervention(s)
Ketorolac: patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection within 6 hours before surgery followed by 30mg im twice daily(at 6:00 AM and 6:00 PM, respectively )for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.
0.9 % saline: 0.9% saline
Study summary
This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 1,346 patients with Stanford Type A aortic dissection, conducted between 2025 and 2028. Participants will receive either ketorolac (60 mg intramuscularly \[IM\] within 6 hours before surgery and 30 mg im twice daily(at 6:00 AM and 6:00 PM, respectively for two days postoperatively or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.
Eligibility
Primary outcome measure(s)
- Primary endpoints — Continuous intervention for 3 days after admission, with a 1-year follow-up.
In-hospital mortality and the occurrence of organ malperfusion syndrome (including myocardial ischemia, stroke, lower limb paralysis, acute abdominal pain, renal failure requiring temporary dialysis, or limb ischemia) during the hospitalization.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Nanjing Drum Tower Hospital | Nanjing | Jiangsu | Recruiting |
More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06968806 on ClinicalTrials.gov ↗ ← All trials in China